CGH
CHRS icon

Crossmark Global Holdings’s Coherus Oncology CHRS Stock Holding History

Crossmark Global Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36,660
Closed -$589K – 1389
2021
Q3 		$589K Hold
36,660
– – 0.01% 840
2021
Q2 		$507K Buy
36,660
+150
+0.4% +$2.12K 0.01% 923
2021
Q1 		$533K Buy
36,510
+40
+0.1% +$679 0.01% 871
2020
Q4 		$634K Buy
+36,470
New +$649K 0.02% 745

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Crossmark Global Holdings's CHRS Position: Q4 2021 in Review

Crossmark Global Holdings sold out of Coherus Oncology (CHRS) in Q4 2021, closing a stake of 36,660 shares — an estimated $589K sold.

Crossmark Global Holdings first reported a position in CHRS in Q4 2020 and held it in 4 quarters. The position peaked at $634K in Q4 2020. 201 funds tracked by Wall St. Rank hold CHRS as of Q4 2021.

  • Crossmark Global Holdings reported no remaining Coherus Oncology position as of Q4 2021 after selling out during the quarter.
  • Crossmark Global Holdings sold 36,660 Coherus Oncology shares in Q4 2021, an estimated $589K.
  • Crossmark Global Holdings first reported a position in Coherus Oncology in Q4 2020 and held it in 4 quarters.
  • Crossmark Global Holdings's Coherus Oncology position peaked at $634K in Q4 2020.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2021.

Based on Crossmark Global Holdings's 13F filing for Q4 2021, filed 10 Jan 2022.